Yıl: 2021 Cilt: 4 Sayı: 2 Sayfa Aralığı: 142 - 146 Metin Dili: İngilizce DOI: 10.32322/jhsm.839303 İndeks Tarihi: 02-08-2021

The impact of laboratory features and comorbidities on the prognosis of patients with COVID-19

Öz:
Objective: Demographic and laboratory values predicting clinical severity in coronavirus disease 2019 (COVID-19) patients havebeen a matter of curiosity since the beginning of the disease. We aimed to show the relationship between the severity of COVID-19disease and comorbidities, clinical and laboratory features of the patients.Material and Method: The data of COVID-19 patients diagnosed with polymerase chain reaction (PCR), were analyzed retrospectively.The patients were divided into 3 groups according to their clinical severity as mild, moderate and severe. Comorbidities and theCharlson comorbidity index (CCI) at the time of diagnosis were calculated for each patient from the patients’ records. Demographicdata, laboratory values, comorbidity and CCI scores were compared between the patient groups. The effect of CCI on survival andlength of hospital stay was examined.Results: One hundred and four patients were included in the trial. The most common comorbid disease in the patients included in thetrial was hypertension. The moderate-severe stage patients were statistically significantly older (p<0.001). The CCI was found to bestatistically significantly different between mild, moderate and severe groups (p<0.001). When CCI increases by one unit, the risk ofdeath increases by 1.193 times (p=0.017). The neutrophil-to-lymphocyte ratio (NLR) was statistically significantly different betweenthe mild, moderate and severe patient groups. It was observed that as the severity of the disease increased, the NLR increased. Olderage, WBC, neutrophil count, NLR, BUN, creatinine, AST, potassium level, C-reactive protein (CRP), procalcitonin, aPTT, fibrinogen,d-dimer, and ferritin levels were found to be higher in the clinically severe patient group. Lymphocyte and eosinophil counts, totalprotein, albumin and sodium levels were found to be lower in the clinically severe patient group.Conclusion: This trial showed that calculating the CCI score in COVID-19 patients can be useful in predicting the severity of thedisease. Examination of CCI, age, WBC, neutrophil, lymphocyte, eosinophil counts, BUN, creatinine, AST, total protein, albumin,sodium, potassium level, CRP, procalcitonin, aPTT, fibrinogen, d-dimer and ferritin levels at the time of diagnosis can be suggested.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507-13.
  • 2. Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus disease 2019 case surveillance—United States, January 22–May 30, 2020. Morb Mortal Wkly Rep 2020; 69: 759.
  • 3. Liao D, Zhou F, Luo L, et al. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol 2020; 7: 671-8.
  • 4. Zhao Q, Meng M, Kumar R, et al. The impact of COPD and smoking history on the severity of COVID-19: a systemic review and meta‐analysis. J Med Virol 2020.
  • 5. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr 2020; 14: 303-10.
  • 6. Matsushita K, Ding N, Kou M, et al. The relationship of COVID-19 severity with cardiovascular disease and its traditional risk factors: A systematic review and meta-analysis. Glob Heart 2020; 15: 64.
  • 7. Ssentongo P, Ssentongo AE, Heilbrunn ES, Ba DM, Chinchilli VM. Association of cardiovascular disease and 10 other preexisting comorbidities with COVID-19 mortality: a systematic review and meta-analysis. PloS one 2020; 15: e0238215.
  • 8. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Clin Epidemiol 1987; 40: 373-83.
  • 9. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal. J Heart Lung Transplant 2020; 39: 405.
  • 10.Chen G, Wu D, Guo W, H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020; 130: 2620-9.
  • 11.Christensen DM, Strange JE, Gislason G, et al. Charlson comorbidity index score and risk of severe outcome and death in Danish COVID-19 patients. J Gen Intern Med 2020; 35: 2801-3.
  • 12.Sun Y, Dong Y, Wang L, et al. Characteristics and prognostic factors of disease severity in patients with COVID-19: The Beijing experience. J Autoimmun 2020: 102473.
  • 13.Garcia PDW, Fumeaux T, Guerci P, et al. Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort. EClinicalMedicine 2020; 25: 100449.
  • 14.Bastug A, Bodur H, Erdogan S, et al. Clinical and laboratory features of COVID-19: predictors of severe prognosis. Int Immunopharmacol 2020; 88: 106950.
  • 15.Liu Y, Du X, Chen J, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect 2020; 81: 6-12.
  • 16.Lagunas‐Rangel FA. Neutrophil‐to‐lymphocyte ratio and lymphocyte‐to‐C‐reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): a meta‐analysis. J Med Virol 2020; 92: 1733-4.
  • 17.Liu J, Liu Y, Xiang P, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med 2020; 18: 1-12.
APA SARICI A, Berber N, ÇAĞASAR Ö, Biçim S, Cagin Y, Ulutaş Ö, Gozukara Bag H, YAKUPOGULLARI Y, BERBER I (2021). The impact of laboratory features and comorbidities on the prognosis of patients with COVID-19. , 142 - 146. 10.32322/jhsm.839303
Chicago SARICI AHMET,Berber Nurcan,ÇAĞASAR Özlem,Biçim Soykan,Cagin Yasir Furkan,Ulutaş Özkan,Gozukara Bag Harika Gozde,YAKUPOGULLARI YUSUF,BERBER Ilhami The impact of laboratory features and comorbidities on the prognosis of patients with COVID-19. (2021): 142 - 146. 10.32322/jhsm.839303
MLA SARICI AHMET,Berber Nurcan,ÇAĞASAR Özlem,Biçim Soykan,Cagin Yasir Furkan,Ulutaş Özkan,Gozukara Bag Harika Gozde,YAKUPOGULLARI YUSUF,BERBER Ilhami The impact of laboratory features and comorbidities on the prognosis of patients with COVID-19. , 2021, ss.142 - 146. 10.32322/jhsm.839303
AMA SARICI A,Berber N,ÇAĞASAR Ö,Biçim S,Cagin Y,Ulutaş Ö,Gozukara Bag H,YAKUPOGULLARI Y,BERBER I The impact of laboratory features and comorbidities on the prognosis of patients with COVID-19. . 2021; 142 - 146. 10.32322/jhsm.839303
Vancouver SARICI A,Berber N,ÇAĞASAR Ö,Biçim S,Cagin Y,Ulutaş Ö,Gozukara Bag H,YAKUPOGULLARI Y,BERBER I The impact of laboratory features and comorbidities on the prognosis of patients with COVID-19. . 2021; 142 - 146. 10.32322/jhsm.839303
IEEE SARICI A,Berber N,ÇAĞASAR Ö,Biçim S,Cagin Y,Ulutaş Ö,Gozukara Bag H,YAKUPOGULLARI Y,BERBER I "The impact of laboratory features and comorbidities on the prognosis of patients with COVID-19." , ss.142 - 146, 2021. 10.32322/jhsm.839303
ISNAD SARICI, AHMET vd. "The impact of laboratory features and comorbidities on the prognosis of patients with COVID-19". (2021), 142-146. https://doi.org/10.32322/jhsm.839303
APA SARICI A, Berber N, ÇAĞASAR Ö, Biçim S, Cagin Y, Ulutaş Ö, Gozukara Bag H, YAKUPOGULLARI Y, BERBER I (2021). The impact of laboratory features and comorbidities on the prognosis of patients with COVID-19. Journal of health sciences and medicine (Online), 4(2), 142 - 146. 10.32322/jhsm.839303
Chicago SARICI AHMET,Berber Nurcan,ÇAĞASAR Özlem,Biçim Soykan,Cagin Yasir Furkan,Ulutaş Özkan,Gozukara Bag Harika Gozde,YAKUPOGULLARI YUSUF,BERBER Ilhami The impact of laboratory features and comorbidities on the prognosis of patients with COVID-19. Journal of health sciences and medicine (Online) 4, no.2 (2021): 142 - 146. 10.32322/jhsm.839303
MLA SARICI AHMET,Berber Nurcan,ÇAĞASAR Özlem,Biçim Soykan,Cagin Yasir Furkan,Ulutaş Özkan,Gozukara Bag Harika Gozde,YAKUPOGULLARI YUSUF,BERBER Ilhami The impact of laboratory features and comorbidities on the prognosis of patients with COVID-19. Journal of health sciences and medicine (Online), vol.4, no.2, 2021, ss.142 - 146. 10.32322/jhsm.839303
AMA SARICI A,Berber N,ÇAĞASAR Ö,Biçim S,Cagin Y,Ulutaş Ö,Gozukara Bag H,YAKUPOGULLARI Y,BERBER I The impact of laboratory features and comorbidities on the prognosis of patients with COVID-19. Journal of health sciences and medicine (Online). 2021; 4(2): 142 - 146. 10.32322/jhsm.839303
Vancouver SARICI A,Berber N,ÇAĞASAR Ö,Biçim S,Cagin Y,Ulutaş Ö,Gozukara Bag H,YAKUPOGULLARI Y,BERBER I The impact of laboratory features and comorbidities on the prognosis of patients with COVID-19. Journal of health sciences and medicine (Online). 2021; 4(2): 142 - 146. 10.32322/jhsm.839303
IEEE SARICI A,Berber N,ÇAĞASAR Ö,Biçim S,Cagin Y,Ulutaş Ö,Gozukara Bag H,YAKUPOGULLARI Y,BERBER I "The impact of laboratory features and comorbidities on the prognosis of patients with COVID-19." Journal of health sciences and medicine (Online), 4, ss.142 - 146, 2021. 10.32322/jhsm.839303
ISNAD SARICI, AHMET vd. "The impact of laboratory features and comorbidities on the prognosis of patients with COVID-19". Journal of health sciences and medicine (Online) 4/2 (2021), 142-146. https://doi.org/10.32322/jhsm.839303